Amyotrophic Lateral Sclerosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of ALS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for other countries.

Clarivate Epidemiology’s ALS forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following ALS subpopulations:

  • Diagnosed prevalent cases by comorbidity status.
  • Diagnosed prevalent cases by subtype status.

Note: Coverage may vary by country.

Table of contents

  • Amyotrophic Lateral Sclerosis - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Prevalence of Definite Amyotrophic Lateral Sclerosis per 100,000 Among Adults in 2020 and 2040
        • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Definite Amyotrophic Lateral Sclerosis Over the Next 20 Years
      • Epidemiology Data
      • Methods
        • Lifetime DALYs Gained
        • Diagnosed Incident Cases (Definite)
        • Diagnosed Incident Cases (Definite + Probable)
        • Diagnosed Prevalent Cases (Definite)
        • Diagnosed Prevalent Cases (Definite + Probable)
        • Subtype Cases
        • Diagnosed Prevalent Cases by Comorbidity
        • Drug-Treated Prevalent Cases of Amyotrophic Lateral Sclerosis
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Amyotrophic Lateral Sclerosis
          • Studies Excluded from the Analysis of Amyotrophic Lateral Sclerosis
        • Risk/Protective Factors
          • Risk/Protective Factors for Amyotrophic Lateral Sclerosis
        • Bibliography
        • Glossary